Mustang Bio Inc (MBIO)
NASDAQ:MBIO
Want to see MBIO full AI Analyst Report?
Top Page
Mustang Bio
(NASDAQ:MBIO)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.67
▼(-38.35% Downside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by weak financial performance (pre-revenue and still cash-burning despite improvement) and bearish technical signals (price below key moving averages and negative MACD). Valuation provides limited support because losses make P/E less meaningful and there is no dividend yield.
Positive Factors
Low leverage / stronger balance sheet
Zero reported debt and a recovery of stockholders’ equity materially reduce solvency risk and interest burden. This improves financial flexibility to fund clinical programs or negotiate collaborations, extending runway and lowering default risk versus prior periods.
Negative Factors
Pre-revenue profile
With no product revenue, the company lacks recurring cash inflows to fund operations. Long-term viability therefore depends on future clinical success and external financing, making operational continuity vulnerable to trial setbacks or capital-market conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / stronger balance sheet
Zero reported debt and a recovery of stockholders’ equity materially reduce solvency risk and interest burden. This improves financial flexibility to fund clinical programs or negotiate collaborations, extending runway and lowering default risk versus prior periods.
Read all positive factors
Mustang Bio (MBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.79M
Dividend YieldN/A
Average Volume (3M)94.14K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS Growth97.67%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,732,120
10 Day Avg. Volume88,215
30 Day Avg. Volume94,141
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.91
Enterprise Value/Market Cap-2.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda3.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mustang Bio Business Overview & Revenue Model
Company Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on g...
How the Company Makes Money
Mustang Bio is a clinical-stage company and, as such, does not have a broadly established, recurring product-revenue base from commercialized therapies. The company has historically funded operations primarily through capital raising (e.g., equity...
Mustang Bio Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -41.00K | 0.00 | -2.23M | -3.03M | -2.31M |
| EBITDA | -3.08M | -2.39M | -14.92M | -48.06M | -71.14M | -64.05M |
| Net Income | -2.72M | -1.92M | -15.75M | -51.60M | -77.53M | -66.37M |
Balance Sheet | ||||||
| Total Assets | 16.58M | 17.59M | 9.31M | 17.74M | 92.42M | 125.17M |
| Cash, Cash Equivalents and Short-Term Investments | 16.26M | 17.27M | 6.84M | 6.23M | 75.66M | 109.62M |
| Total Debt | 0.00 | 0.00 | 878.00K | 2.50M | 31.38M | 2.03M |
| Total Liabilities | 7.99M | 8.06M | 13.18M | 17.62M | 46.15M | 12.77M |
| Stockholders Equity | 8.60M | 9.53M | -3.87M | 123.00K | 46.27M | 112.40M |
Cash Flow | ||||||
| Free Cash Flow | -4.88M | -5.26M | -11.41M | -49.59M | -68.14M | -59.03M |
| Operating Cash Flow | -4.88M | -5.26M | -11.41M | -49.48M | -65.07M | -53.67M |
| Investing Cash Flow | 0.00 | 1.17M | 0.00 | 5.89M | -2.95M | -5.37M |
| Financing Cash Flow | 6.91M | 14.53M | 11.27M | -26.08M | 34.06M | 70.85M |
Mustang Bio Technical Analysis
Negative
1.09
Price Trends
0.74
Negative
0.86
Negative
1.14
Negative
Market Momentum
-0.04
Positive
37.11
Neutral
32.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBIO, the sentiment is Negative. The current price of 1.09 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.74, and below the 200-day MA of 1.14, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 37.11 is Neutral, neither overbought nor oversold. The STOCH value of 32.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBIO.
Mustang Bio Risk Analysis
Mustang Bio disclosed 65 risk factors in its most recent earnings report. Mustang Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mustang Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $8.47M | -0.83 | -291.07% | ― | ― | 68.70% | |
43 Neutral | $4.79M | -1.28 | -418.83% | ― | ― | 97.67% | |
| ― | $6.24M | -5.61 | ― | ― | ― | ― | |
46 Neutral | $2.09M | -0.38 | -529.06% | ― | ― | 96.81% | |
43 Neutral | $9.51M | -0.26 | -97.58% | ― | 78.64% | 50.70% | |
40 Underperform | $1.33M | -1.72 | 1211.14% | ― | -74.05% | 73.08% |
* Healthcare Sector Average
MBIO
Mustang Bio
0.62
-0.67
-51.78%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.38
-2.14
-47.35%
LYRA
Lyra Therapeutics
0.70
-3.69
-84.05%
BOLT
Bolt Biotherapeutics
5.13
-1.27
-19.84%
SLXN
Silexion Therapeutics
0.43
-14.72
-97.17%
ACXP
Acurx Pharmaceuticals
1.94
-5.94
-75.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.